Dermatica cream review: SmartBase, active choices and two bottles

The opening heading names a Retinal 0.05%–0.2% Serum. Elsewhere, the same anti-aging page describes a personalized treatment with prescription ingredients and a hydrating SmartBase cream. Those are different descriptions. The retail serum’s name cannot establish that it is the prescribed tretinoin preparation, and its introductory claims should not silently become evidence for that cream. Dermatica treatment page

This review concerns the personalized prescription narrative. It is a service-defined preparation rather than one fixed retail serum. The options comparison can be read alongside it, while the Hims review provides another distinct cream record to consider without treating the two providers’ formulas as interchangeable. Dermatica treatment page

The page presents entries for azelaic acid, hydroquinone and tretinoin, including a published tretinoin range of 0.025%–0.1%. It describes ingredients selected for the person’s skin. Reading all the entries as one mixture would erase that selection step and assign a combination that the public menu does not itself confirm. Dermatica treatment page

The ingredient page separately attributes a two-to-three-active approach to a dermatologist. That adds context about formulation choices; it does not disclose every patient’s actives or concentrations. Our strength and vehicle discussion treats a published strength range as part of a description, rather than a way to rank preparations or choose a prescription. Dermatica ingredients

Both the treatment and ingredient pages identify hyaluronic acid, ceramides, glycerin and panthenol in SmartBase. The ingredient page also uses alcohol-free and fragrance-free claims. These are more informative than simply calling the treatment hydrating: they name part of the carrier and describe characteristics that the company attributes to its formulation. Dermatica treatment page Dermatica ingredients

They remain highlights rather than a complete inactive declaration in the selected description. A base can have other components beyond the four emphasized names. Nor do those names establish that the finished prescription prevents irritation. The combination-ingredient guide explains why a rationale for added components is distinct from a tested result for a mixture. Dermatica ingredients

The treatment page says the bespoke plan arrives with two bottles approximately every 56 days. The pricing page displays $29.95 per bottle and $59.90 every two months for its two-month plan, with free shipping. Keeping the bottles, charge and period together gives a clearer picture than repeating a monthly figure by itself. Dermatica treatment page Dermatica pricing

No exact mass or volume for either bottle is established by these descriptions. The approximately 56-day delivery statement also cannot establish a shelf life or the amount someone should use. FDA’s explanation of stability ties dating to a specified product and its labeled conditions, rather than the time between commercial shipments. Dermatica pricing FDA stability explanation

Dermatica says it monitors progress, adjusts treatment as needed and provides access to dermatology experts. Its plan descriptions also allow delivery changes, pauses and cancellation. Those features explain how the service is advertised to continue after the first formulation, rather than suggesting that the first ingredient menu is permanently fixed. Dermatica treatment page Dermatica pricing

An individual prescription and pharmacy record would establish what was actually selected at a particular point. This publication has not observed an adjustment or tested a response. The Curology preparation review offers a related reading question: how can a current formula be distinguished from a differently dated public description? Dermatica treatment page FDA pharmacist guidance

The SmartBase ingredient section includes the phrase FDA REGULATED. It appears alongside formulation and packaging claims, not as an approval record for a specific personalized prescription. That distinction matters because a regulatory phrase can sound broader than the evidence supplied by a treatment description or a list of available ingredients. Dermatica ingredients

FDA’s compounding explanation says compounded drugs are not FDA-approved and distinguishes them from approved generics. This does not independently classify or audit a particular Dermatica supply. It does mean that the ingredient page’s phrase should not be presented as proof that the finished personalized mixture has passed FDA review for safety, effectiveness and quality. FDA compounding explanation

The public record gives Dermatica a recognizable proposition: selected prescription ingredients in SmartBase, a two-bottle plan and ongoing formula adaptations. The most useful unanswered fields are the complete selected base, the actives and their strengths, the amount in each bottle and the record accompanying the supplied prescription. Dermatica treatment page Dermatica ingredients Dermatica pricing

The dispensing-record article explains why those fields belong together. FDA describes pharmacists as a resource when prescription, pharmacy and online information conflict. This review can clarify the published offer, while a pharmacist or prescriber would need the exact preparation to explain an individual discrepancy or its product-specific dating information. FDA pharmacist guidance FDA stability explanation